Governments recognize the public health impact of influenza and the potential economic burden associated with flu-related healthcare costs and productivity losses. Consequently, several governments implement vaccination programs to provide free or subsidized influenza vaccines to specific demographics, such as the elderly, healthcare workers, and high-risk individuals. These programs aim to increase vaccination coverage, reduce the incidence of influenza-related complications, and support the growth of this market.
Also, the development of quadrivalent vaccines that protect against four influenza strains instead of three has become more common. Therefore, the ongoing research and development efforts in vaccine technology contribute to improved efficacy, durability of protection, and patient compliance, driving the overall market demand.
However, the high cost associated with vaccine development and longer vaccine production timelines may hamper the industry landscape.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The influenza vaccines market size was worth USD 7.1 billion in 2023 and is anticipated to be USD 13 billion by 2032, owing to the increasing prevalence of influenza.
The egg-based segment is anticipated to reach USD 10.8 billion by 2032, as these vaccines have been a longstanding and well-established method allowing for large-scale vaccine manufacturing.
North America influenza vaccines market is anticipated to grow at CAGR 6.5% through 2032, attributed to well-established healthcare infrastructure with numerous hospitals, clinics, and pharmacies.
AstraZeneca plc., Viatris Inc., CSL Limited, Sinovac Biotech Ltd., Emergent Biosolutions, Sanofi SA, Gamma Vaccines Pty Ltd., Novartis AG, GlaxoSmithKline plc and Merck & Co., Inc.